BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hellmich B, Águeda AF, Monti S, Luqmani R. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. Curr Rheumatol Rep 2020;22:84. [PMID: 33044642 DOI: 10.1007/s11926-020-00964-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Kramarič J, Rotar Ž, Tomšič M, Hočevar A. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1069013] [Reference Citation Analysis]
2 Cicco S, Desantis V, Vacca A, Cazzato G, Solimando AG, Cirulli A, Noviello S, Susca C, Prete M, Brosolo G, Catena C, Lamanuzzi A, Saltarella I, Frassanito MA, Cimmino A, Ingravallo G, Resta L, Ria R, Montagnani M. Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis. Front Med (Lausanne) 2022;9:863150. [PMID: 35652080 DOI: 10.3389/fmed.2022.863150] [Reference Citation Analysis]
3 Qiao X, He S, Altawil A, Wang QY, Kang J, Li WY, Yin Y. Multisystemic Sarcoidosis Presenting With Leg Ulcers, Pancytopenia, and Polyserositis Was Successfully Treated With Glucocorticoids: A Case Report and Literature Review. Front Med (Lausanne) 2021;8:803852. [PMID: 35242768 DOI: 10.3389/fmed.2021.803852] [Reference Citation Analysis]
4 Dhanani U, Zhao MY, Charoenkijkajorn C, Pakravan M, Mortensen PW, Lee AG. Large-Vessel Vasculitis in Ophthalmology: Giant Cell Arteritis and Takayasu Arteritis. Asia Pac J Ophthalmol (Phila) 2022;11:177-83. [PMID: 35533336 DOI: 10.1097/APO.0000000000000514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hellmich B, Henes JC. [Biologics for connective tissue diseases and vasculitides]. Internist (Berl) 2022. [PMID: 35029701 DOI: 10.1007/s00108-021-01249-w] [Reference Citation Analysis]
6 Alušík Š. Giant cell arteritis: controversial issues. Vnitr Lek 2021;67:224-229. [DOI: 10.36290/vnl.2021.057] [Reference Citation Analysis]
7 Wu S, Kong X, Cui X, Chen H, Ma L, Dai X, Ji Z, Yan Y, Huang Q, Sun Y, Jiang L. Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population. Joint Bone Spine 2021;88:105186. [PMID: 33892193 DOI: 10.1016/j.jbspin.2021.105186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ni A, Chen L, Huang X, Ma Y, Lan L, Ren P, Wang Y, Zhu Y, Xu Y, Chen J, Han F. The risk factors for early mortality and end-stage renal disease in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: experiences from a single center. Clin Exp Med 2021;21:389-97. [PMID: 33768341 DOI: 10.1007/s10238-021-00690-3] [Reference Citation Analysis]
9 Hellmich B. [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?]. Z Rheumatol 2021;80:322-31. [PMID: 33710440 DOI: 10.1007/s00393-021-00975-8] [Reference Citation Analysis]